Which platelet function test best reflects the in vivo plasma concentrations of ticagrelor and its active metabolite?

Summary

Aim of this study was assessment of the relationship between concentrations of ticagrelor and its active metabolite (AR-C124910XX) and results of selected platelet function tests. In a single-centre, cohort study, patients with myocardial infarction underwent blood sampling following a 180 mg ticagrelor loading dose intake (predose, 1, 2, 3, 4, 6, 12, 24 hours postdose) to perform pharmacokinetic and pharmacodynamic assessments. Platelet reactivity was evaluated using the VASP-assay, the VerifyNow device and the Multiplate analyzer. Analysis of 36 patients revealed high negative correlations between ticagrelor concentrations and platelet reactivity evaluated with all three platelet function tests (the VASP-assay: RS=-0.722; p<0.0001; the VerifyNow device: RS=-0.715; p<0.0001; the Multiplate analyzer: RS=-0.722; p<0.0001), with no significant differences between correlation coefficients. Similar results were found for AR-C124910XX. Platelet reactivity values assessed with all three methods generally correlated well with each other; however, a significantly higher correlation (p<0.02) was demonstrated between the VerifyNow and Multiplate tests (RS=0.707; p<0.0001) than in other assay combinations (the VASP-assay and the VerifyNow device: RS=0.595; p<0.0001; the VASP-assay and the Multiplate analyzer: RS=0.588; p<0.0001). With respect to the recognition of high platelet reactivity, we found higher measurement concordance between the VerifyNow and Multiplate tests compared with other assay combinations, while for low platelet reactivity, only results of the VerifyNow and Multiplate assay were related to each other. Platelet reactivity measurements performed with the VASP, VerifyNow and Multiplate tests show comparably strong negative correlations with ticagrelor and AR-C124910XX concentrations.

Study registration: ClinicalTrials.gov identifier NCT02690454.

 

MissingLinkText

Keywords

Ticagrelor - AR-C124910XX - flow cytometric VASP-assay - VerifyNow device - Multiplate analyzer

 

 

MissingLinkText

Conflicts of interest

Dr Marek Koziński received honoraria for lectures from Astra-Zeneca. Dr Jacek Kubica received a consulting fee from Astra-Zeneca. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

• References

• 1 Roffi M, Patrono C, Collet JP. et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2016; 37: 267-315.
• 2 Steg PG, James SK, Atar D. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-2619.
• 3 Gurbel PA, Bliden KP, Butler K. et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopido-grel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009; 120: 2577-2585.
• 4 Wallentin L, Becker RC, Budaj A. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
• 5 Aradi D, Kirtane A, Bonello L. et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 2015; 36: 1762-1771.
• 6 Aradi D, Storey RF, Komócsi A. et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J 2014; 35: 209-215.
• 7 Aradi D, Collet JP, Mair J. et al. Platelet function testing in acute cardiac care - is there a role for prediction or prevention of stent thrombosis and bleeding?. Thromb Haemost 2015; 113: 221-230.
• 8 Tantry US, Bonello L, Aradi D. et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013; 62: 2261-2273.
• 9 Storey RF, Angiolillo DJ, Bonaca MP. et al. Platelet inhibition with ticagrelor 60 mg versus 90 mg twice daily in the PEGASUS-TIMI 54 Trial. J Am Coll Cardiol 2016; 67: 1145-1154.
• 10 Which platelet function test best reflects the in vivo plasma concentrations of ti-cagrelor and its active metabolite? The HARMONIC study. ClinicalTrials.gov Identifier: NCT02690454 https://clinicaltrials.gov/ct2/show/NCT02690454?term=NCT02690454&rank=1 Accessed August 16, 2016.
• 11 Thygesen K, Alpert JS, Jaffe AS. et al. Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. Eur Heart J 2012; 33: 2551-2567.
• 12 Kubica J, Adamski P, Ostrowska M. et al. Morphine delays and attenuates ti-cagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J 2016; 37: 245-252.
• 13 Koziński M, Obońska K, Stankowska K. et al. Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up. Cardiol J 2014; 21: 547-556.
• 14 Mangiacapra F, Patti G, Barbato E. et al. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYo-cardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study. JACC Cardiovasc Interv 2012; 05: 281-289.
• 15 Bonello L, Mancini J, Pansieri M. et al. Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel. J Thromb Haemost 2012; 10: 1999-2005.
• 16 Stone GW, Witzenbichler B, Weisz G. et al. ADAPT-DES Investigators. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-elut-ing stents (ADAPT-DES): a prospective multicentre registry study. Lancet 2013; 382: 614-623.
• 17 Siller-Matula JM, Hintermeier A, Kastner J. et al. Distribution of clinical events across platelet aggregation values in all-comers treated with prasugrel and ti-cagrelor. Vascul Pharmacol 2016; 79: 6-10.
• 18 Alexopoulos D, Stavrou K, Koniari I. et al. Ticagrelor vs prasugrel one-month maintenance therapy: impact on platelet reactivity and bleeding events. Thromb Haemost 2014; 112: 551-557.
• 19 Windecker S, Kolh P, Alfonso F. et al. 2014 ESC/EACTS Guidelines on myo-cardial revascularization. Eur Heart J 2014; 35: 2541-2619.
• 20 Price MJ, Berger PB, Teirstein PS. et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. J Am Med Assoc 2011; 305: 1097-1105.
• 21 Trenk D, Stone GW, Gawaz M. et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 2012; 59: 2159-2164.
• 22 Collet JP, Cuisset T, Rangé G. et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012; 367: 2100-2109.
• 23 Bouman HJ, Parlak E, van Werkum JW. et al. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. J Thromb Haemost 2010; 08: 482-488.
• 24 Liang Y, Johnston M, Hirsh J. et al. Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopi-dogrel and aspirin. J Thromb Thrombolysis 2012; 34: 429-436.
• 25 Delavenne X, Mallouk N, Piot M. et al. Is there really a relationship between the plasma concentration of the active metabolite of clopidogrel and the results of platelet function tests?. J Thromb Haemost 2010; 08: 2334-2338.
• 26 Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable angina, NSTEMI and STEMI undergoing PCI. ClinicalTrials.gov Identifier: NCT02012140 https://clinicaltrials.gov/ct2/show/NCT02012140?term=NCT02012140&rank=1 Accessed August 16, 2016.
• 27 Comparison of ticagrelor pharmacokinetics and pharmacodynamics in STEMI and NSTEMI patients (PINPOINT). ClinicalTrials.gov Identifier: NCT02602444 https://clinicaltrials.gov/ct2/show/NCT02602444?term=NCT02602444&rank=1 Accessed August 16, 2016.
• 28 Alexopoulos D, Xanthopoulou I, Gkizas V. et al. Randomized assessment of ti-cagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elev-ation myocardial infarction. Circ Cardiovasc Interv 2012; 05: 797-804.
• 29 Parodi G, Valenti R, Bellandi B. et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 2013; 61: 1601-1606.